FDA Clears Class II Status for Hyperhidrosis Skin Patch
Published Date: 6/30/2026
Rule
Summary
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Skin Patch Reclassified to Class II
The FDA officially classified the skin patch for treating hyperhidrosis as a Class II device with special controls, effective June 30, 2026 (classification applicable April 7, 2023). FDA says this lower-classification reduces regulatory burdens and will enhance patients' access to the treatment.
De Novo Creates Easier Path For Firms
FDA used the De Novo process for the N-SWEAT Patch, which means that this device type can serve as a predicate for future devices so other sponsors may use the less-burdensome 510(k) pathway instead of De Novo or premarket approval. FDA issued the De Novo order April 7, 2023 and this classification is codified effective June 30, 2026.
Premarket 510(k) Requirement Remains
FDA states that skin patches for treatment of hyperhidrosis are subject to premarket notification under section 510(k) of the FD&C Act because FDA has not exempted this device type under section 510(m).
Required Safety, Testing, and Labeling Rules
FDA lists special controls that manufacturers must meet: clinical performance testing (including validated measures of reduction in hyperhidrosis and adverse events), non-clinical thermal and performance testing, biocompatibility, shelf-life testing, and patient and physician labeling that lists risks, duration of effect, disposal instructions, and a shelf life.
Device Is Prescription-Only
At the time of classification, FDA identifies skin patches for hyperhidrosis as prescription topical patches only. That means you must obtain a prescription from a clinician to use this device.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19654, Naveed Aslam: Final Debarment Order
The FDA has permanently banned Dr. Naveed Aslam from working with any drug companies because he was convicted of a serious crime related to drug regulations. He didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on September 25, 2026. Dr. Aslam can apply to end this ban anytime, but it won’t be easy or quick.
2026-19660, Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments
The FDA is gearing up to renew the Biosimilar User Fee Act, which helps fund the review of biosimilar drug applications. This affects drug makers and the public by ensuring faster, smoother approval processes from 2028 to 2032. They’re hosting a public meeting on October 26, 2026, and want your comments by November 25, 2026, to shape the future of this important program.
Previous / Next Documents
Previous: 2026-13137, Marine Casualty Reporting on the Outer Continental Shelf
Starting July 30, 2026, companies working on the Outer Continental Shelf must report marine accidents based on who’s involved, not just where they happen. The rule raises the damage cost that triggers a report from $25,000 to $75,000, saving businesses money and making rules clearer and fairer. This change cuts industry costs by over $10,000 in 10 years and aligns U.S. rules with international standards for offshore activities.
Next: 2026-13140, Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.